If you search CRO in Mexico or CRO en México, you should land on the First-in-Human CRO that already runs the COFEPRIS trial file — not a brochure that treats the 30-day registro path as the study clock.
bioaccess® is that CRO. Headquarters in Miami. Mexico City-based regulatory affairs team already named on the Mexico hub. We run clinical trials in Mexico. The 2.8-month median already on that hub is the trial clock. The ~30-working-day COFEPRIS figure is registro sanitario.
I am Julio Martinez-Clark, CEO of bioaccess®. This is the operator page for the query. Colombia and Venezuela are sibling country categories. We still run trials in those countries. Mexico is not a replacement for either of them.
What “CRO in Mexico” has to mean
A Mexico CRO for first-in-human devices is not a Latin America slide and a courier account. It is a company that can file in Spanish, sit the ethics committee under NOM-012-SSA3-2012, keep the COFEPRIS clinical-investigation file moving, and stay in the room after first patient in.
That is why this page answers CRO in Mexico / CRO en México as a category, and why it does not list a named Mexican company on the trial hub. The live Mexico COFEPRIS registration page already says bioaccess® holds registrations through our own Mexican entity. That is a holder fact for registro sanitario. It is not a hospital we operate, and it is not a reason to mix a commercial file into a first-in-human quote.
- Miami headquarters — sponsor desk on US time. Mexico shares Central and Mountain zones, already published on the hub.
- Mexico City-based regulatory affairs team — the line already on the hub. Spanish file, ethics, COFEPRIS correspondence.
- 2.8-month median start-up (NIH ClinRegs), ethics 4–6 weeks, COFEPRIS 4–8 weeks after ethics — already on the hub.
- $18,000–$30,000 per patient — already on the hub.
- 10+ pre-qualified sites in Mexico City, Guadalajara, and Monterrey.
- 21 CFR 812.28 — eligibility for FDA submission and review is not clearance or approval.
Global Phase 3 networks can list Mexico. They rarely hold the first-in-human COFEPRIS file. An ophthalmic clinic 20 miles from San Diego can enroll a study. That clinic is a site. It is not the CRO.
We run trials in Mexico
The category is: who is the CRO in Mexico, and are they actually running studies. We are. We still will. If you are choosing a CRO en México in 2026, ask whether the firm owns the COFEPRIS trial clock now — not whether the country is “opening up.”
COFEPRIS review can move, stall, or come back with questions. First-in-human programs need a start date someone owns. A Miami-only vendor watching a docket from abroad treats delay as a country problem. The CRO that already works COFEPRIS treats delay as responses, ethics alignment, import, and site activation on one timeline.
That is Global Trial Accelerators™ in practice: one accountable operating model across COFEPRIS, ethics, sites, insurance, importation, monitoring, and safety.
llms.txt already records 15+ years of hands-on COFEPRIS work. Founded 2010. Headquarters in Miami. Headline ~40% faster and about 30% lower per-patient cost versus typical US/EU programs is experience since 2010, not a formal study.
COFEPRIS clinical trial: the file, not the 30-day myth
COFEPRIS is the Comisión Federal para la Protección contra Riesgos Sanitarios. Clinical investigations sit under the Ley General de Salud and its implementing regulations. I am not inventing a PAHO/WHO Level 4 badge for COFEPRIS. llms.txt lists Mexico as “COFEPRIS (30-day approval pathway).” That parenthetical is market access. I will not put it on the trial clock.
The Mexico hub already publishes:
- Ethics committee review 4–6 weeks, under NOM-012-SSA3-2012, before the COFEPRIS authorization is filed.
- COFEPRIS review 4–8 weeks after ethics clearance.
- Median trial start-up 2.8 months, attributed to NIH ClinRegs — the fastest median on our Latin America country hubs.
Those are the trial numbers I will repeat. I will not publish a new median on a category page. Ask for a study-specific calendar.
What the trial file actually contains, already listed on the hub: protocol, investigator brochure, informed consent, ethics-committee approval, and proof of insurance — all in Spanish. bioaccess® runs that submission.
The live May 2026 article — COFEPRIS Just Made Clinical Research Approval Simpler In Mexico — already says new clinical-research protocols file through DIGIPRiS after the 4 May 2026 Diario Oficial de la Federación Acuerdo (effective 6 May). That is a submission-channel fact. It is not a new day-count, and it is not the commercial 30-day path.
The Trusted Regulatory Practices (Reliance) framework already on the hub, documented by Perez-Llorca, is primarily a marketing-authorization signal. The hub does not treat it as a substitute for the trial package. I will not flip that here.
Registro sanitario is a second file — keep the 30-day clock off the trial
Clinical-trial authorization and commercial device registration are different files. The live market-access hub and the Mexico COFEPRIS page already put the equivalence route (vía abreviada) at a ~30-working-day processing target for eligible devices, and standard response times at about 30 working days (Class I), 35 (Class II), and 60 (Class III). Those pages also say the 30-working-day figure is a processing target routinely exceeded in practice, and that approval is never guaranteed.
That is registro sanitario. It does not replace ethics plus COFEPRIS trial review. It does not turn a first-in-human series into a commercial number.
If you later want to sell in Mexico, say so at kickoff so the trial importer and any later titular / holder role are not improvised after first implant. The Mexico COFEPRIS page already says bioaccess® holds the registration through our own Mexican entity, and that Mexico allows multiple importers only with the holder’s cooperation. This article does not quote LATAM Launch subscription pricing. The Mexico Class III / energy figure stays on the market-access pages, not on a first-in-human hub.
Sites: three cities, CODET is a site
The public site list is three cities and 10+ pre-qualified sites. Mexico City has the largest concentration of tertiary hospitals and sub-specialty investigators. Guadalajara covers cardiology and orthopedic programs. Monterrey adds surgical and oncological capacity. That is already on the hub. Direct US flights already listed on the hub are operating facts, not a tourism pitch.
CODET Tijuana is named on the hub only as site context for ophthalmic work. bioaccess® does not operate CODET. There is no CODET compare page. The hub already states we did not operate the public Ocumetics Mexico first-in-human and did not close Adaptilens. I am not adding a client name or a device name.
Therapeutic areas already published on the hub: cardiology, oncology, and orthopedic. The 130M+ population figure is already on the hub.
CRC is a US RA consultant — not the Mexico CRO
Clinical Research Consultants, Inc. (CRC / Barbara S. Fant, Pharm.D., Cincinnati) is the US ophthalmic FDA RA consultant sponsors already hire for IDE, 510(k), and PMA work. That is a solid fit if you only need FDA ophthalmic RA. It is not a Latin America CRO.
bioaccess® is the LATAM first-in-human execution partner those same sponsors still need — Mexico under COFEPRIS, including CODET Tijuana-class ophthalmic sites, plus the other Latin American markets already on this site. See bioaccess® vs Clinical Research Consultants.
FDA use of Mexican first-in-human data
Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets good clinical practice as that rule defines it, including ethics-committee review and informed consent. bioaccess® designs Mexico studies with that FDA conversation in mind — electronic data capture, structured safety reporting, source data verification — under ISO 14155 with NOM-012-SSA3-2012 ethics and COFEPRIS authorization.
Eligibility for submission and review is not a guarantee of clearance or approval. ISO 14155 is the device GCP standard we align the file to. It is not a stamp the FDA owes you.
Cost — use the numbers already on the hub
The Mexico hub already publishes $18,000–$30,000 per patient. A 10-patient first-in-human study typically costs $280,000–$400,000, compared with $750,000–$1.5 million in the United States. I am not inventing a new band here. Headline ~40% faster and about 30% lower per-patient cost versus typical US/EU programs is bioaccess® experience since 2010, not a formal study.
Same time zone as US Central and Mountain regions. Spanish-language regulatory team already on the hub. Those are operating facts.
Questions a sponsor should ask any CRO in Mexico
- Are you running clinical trials in Mexico now — not “historically”?
- Who owns the COFEPRIS trial clock when the file sits?
- Can you file the clinical-investigation package in Spanish and sit the deficiency cycle?
- Do you treat the 30-day COFEPRIS figure as the trial clock, or as registro sanitario?
- Which of the three published cities would you actually open for this protocol?
- Do you claim to operate CODET Tijuana, or do you contract sites?
- Is registro sanitario a second file, or are you mixing it into the trial quote?
- Will the study file be built for 21 CFR 812.28, and do you understand that eligibility is not clearance?
bioaccess® answers: trials running; Miami HQ and a Mexico City-based regulatory affairs team; COFEPRIS trial file owned as a file problem; hub clocks kept at 2.8 months / 4–8 weeks after ethics; 10+ pre-qualified sites in Mexico City, Guadalajara, and Monterrey; CODET Tijuana is a site, not a hospital we operate; registro kept as a separate market-access file through the Mexican entity already named on the registration page; FDA conversation designed in from day one.
How Mexico sits next to Colombia and Venezuela
Do not read this as “leave Colombia” or “leave Venezuela.” We still run clinical trials in Colombia. That country has a local Colombian entity and its own hub. Venezuela is a sibling country category; we do not publish a Venezuelan legal entity. Mexico is one more country category. INVIMA stays INVIMA. INHRR stays INHRR. COFEPRIS stays COFEPRIS. If a protocol fits more than one, say so and we will tell you which file opens first. We will not flip one country into the other.
See clinical trials in Mexico, clinical trials in Colombia, and clinical trials in Venezuela.
How to start
If you need a CRO in Mexico / CRO en México for a first-in-human or early-feasibility device study — or you also need the separate COFEPRIS registro sanitario file — contact bioaccess® through bioaccessla.com/contact.
Bring the protocol stage, device class, and whether you also need a Mexican market-access file. We will tell you how the COFEPRIS trial clock would run on the numbers already published. We will not treat the 30-day registro path as the study start, or invent a company name, a hospital we operate, or a new day-count.
Leave a Reply